Compare UK prices. 40+ products · 17 retailers scored
PeptideClear UK

NHS access decoder

NHS GLP-1 access by nation

OM

Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)

Last updated 2026-05-20

NHS access to GLP-1 weight-loss medications (semaglutide and tirzepatide, branded Wegovy and Mounjaro) differs by UK nation. England is rolling out tirzepatide in phased cohorts via primary care, with full eligibility scheduled to take 9 to 12 years. Scotland funds it only through specialist weight-management services at lower BMI thresholds. Wales is implementing slowly through specialist tiers. Northern Ireland has no funded NHS route at present. PeptideClear summarises each nation's current eligibility and access path, last reviewed May 2026.

POM: Prescription only medicine (POM). PeptideClear is a comparison and information service. We do not prescribe, dispense, or recommend medication for individuals. A qualified GMC-registered prescriber determines suitability after consultation.

England

Cohort 1 live since June 2025. Cohort 2 launches 23 June 2026.

BMI:
BMI 40+ for Cohort 1 (Cohort 2 expected to broaden to BMI 35+ with comorbidities).
Route:
GP referral to NHS weight management specialist service. No GP-prescribing route yet.
Medication:
Tirzepatide (Mounjaro) per NICE TA1026.

Phased rollout means most adults outside Cohort 1 cannot access NHS GLP-1 yet. Ethnicity-adjusted BMI applies (2.5 kg/m² lower for South Asian, Chinese, Black African, African-Caribbean populations).

Scotland

Cleared by SMC for use, BMI 30+ specialist-only.

BMI:
BMI 30+ in adults, with at least one weight-related comorbidity, in specialist services.
Route:
Specialist weight management service referral, not GP. Variation by health board.
Medication:
Tirzepatide (Mounjaro). Wegovy also approved.

Scotland uses Right Decisions guidance. Patients in Scotland may have lower BMI threshold than England, but capacity at specialist services is the bottleneck.

Wales

NICE TA1026 implementation in progress 2026.

BMI:
Following NICE TA1026 (BMI 35+ with comorbidity, ethnicity-adjusted).
Route:
Health board specialist service. Cardiff and Vale, Aneurin Bevan, Betsi Cadwaladr at different stages.
Medication:
Tirzepatide (Mounjaro).

Wales is implementing TA1026 on a slower timeline than England. Postcode-by-postcode variation by local health board.

Northern Ireland

No NHS GLP-1 access yet. First specialist service planned 2026.

BMI:
TBD. Likely to mirror NICE TA1026 once funding is in place.
Route:
Currently no NHS route. Patients must use private route.
Medication:
Pending.

Northern Ireland HSC has not yet announced an NHS GLP-1 weight management programme. Several private pharmacies dispense in NI but cold-chain delivery has postcode exclusions.

Popular on PeptideClear

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-20